PTJ
TBPH icon

Paul Tudor Jones’s Theravance Biopharma TBPH Stock Holding History

Paul Tudor Jones’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Sell
60,425
-59,697
-50% -$988K ﹤0.01% 2399
2026
Q1 		$1.95M Sell
120,122
-70,007
-37% -$1.24M ﹤0.01% 1877
2025
Q4 		$3.56M Buy
190,129
+139,081
+272% +$2.31M 0.01% 1377
2025
Q3 		$745K Sell
51,048
-145,515
-74% -$1.84M ﹤0.01% 2466
2025
Q2 		$2.17M Sell
196,563
-10
-0% -$97 ﹤0.01% 1610
2025
Q1 		$1.76M Sell
196,573
-5
-0% -$47 0.01% 1439
2024
Q4 		$1.85M Hold
196,578
– – 0.01% 1315
2024
Q3 		$1.58M Buy
196,578
+2,810
+1% +$24.3K 0.01% 1345
2024
Q2 		$1.64M Buy
193,768
+16,156
+9% +$146K 0.01% 1183
2024
Q1 		$1.59M Buy
177,612
+167,529
+1,661% +$1.55M 0.01% 1128
2023
Q4 		$113K Sell
10,083
-97,665
-91% -$983K ﹤0.01% 2242
2023
Q3 		$930K Sell
107,748
-13,918
-11% -$134K 0.01% 1339
2023
Q2 		$1.26M Buy
121,666
+13,031
+12% +$144K 0.02% 1177
2023
Q1 		$1.18M Buy
108,635
+15,201
+16% +$161K 0.02% 1097
2022
Q4 		$1.05M Buy
+93,434
New +$982K 0.02% 1074
2022
Q3 		– Sell
-103,280
Closed -$936K – 2696
2022
Q2 		$936K Buy
103,280
+71,364
+224% +$658K 0.02% 931
2022
Q1 		$305K Sell
31,916
-141,498
-82% -$1.39M 0.01% 1545
2021
Q4 		$1.92M Buy
173,414
+121,705
+235% +$1.06M 0.03% 655
2021
Q3 		$383K Buy
+51,709
New +$578K 0.01% 1846
2015
Q3 		– Sell
-27,800
Closed -$362K – 1742
2015
Q2 		$362K Buy
+27,800
New +$431K 0.01% 992

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Paul Tudor Jones's TBPH Position: Q2 2026 in Review

Paul Tudor Jones reduced its Theravance Biopharma (TBPH) stake by 50% in Q2 2026, selling an estimated $988K and leaving 60,425 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2399.

Paul Tudor Jones first reported a position in TBPH in Q2 2015 and has held it in 20 quarters since. The position peaked at $3.56M in Q4 2025. 178 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Paul Tudor Jones held 60,425 shares of Theravance Biopharma worth $1.03M as of Q2 2026.
  • Paul Tudor Jones sold 59,697 Theravance Biopharma shares in Q2 2026, an estimated $988K.
  • Theravance Biopharma made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2399 holding.
  • Paul Tudor Jones first reported a position in Theravance Biopharma in Q2 2015 and has held it in 20 quarters since.
  • Paul Tudor Jones's Theravance Biopharma position peaked at $3.56M in Q4 2025.
  • 178 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.